Cellectis CEO says company's core remains gene-editing
Cellectis (CLLS) develops immunotherapies based on gene-edited CAR T-cells. In an exclusive interview with The Fly, the company's CEO Andre Choulika talked about the company's focus on gene-editing: "Well Cellectis is a biotech company that had been founded as a gene editing company and I think we're the first gene-editing company to ever be founded. That was like close to 20 years ago and since then we have kept the core technology of the company in gene-editing. Today 100% of our products are in oncology, 100% of them are CAR-T therapies and 100% of the indications are liquid tumors. Nevertheless, the core remains gene-editing and we potentially will expand outside oncology and other types of indications using gene-editing as the core technology there." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.